source
- Cellectis abandons CAR-T programs, shifts focus to in vivo gene editingCellectis announced it will discontinue its donor-derived CAR‑T programs and redirect its efforts toward in vivo gene‑editing medicines. The company said the commercial and clinical landscape for…
- FDA appoints new oncology chief, pledges ongoing innovation; approves treatments for two rare genetic disordersThe Food and Drug Administration has announced a new leader for its Oncology Center of Excellence. The appointee emphasized a continued focus on innovative cancer therapies and collaborative resear…